Table 3.
Vaccination visits | Incomplete vaccination status | Risk difference for incomplete vaccination status | Relative risk of incomplete vaccination status | % of cases exposed | Attributable risk in the population | ||
---|---|---|---|---|---|---|---|
With a new vaccine delay % (n/N) |
Without a vaccine delay % (n/N) |
Unadjusted | Adjustedb (95% CI) | Adjustedb (95% CI) | Adjusted (95% CI)c | ||
DTaP at 2 months | 46.4% (96/207) | 11.1% (361/3250) | 35.3% | 27.7% (22.2%; 28.2%) | 3.6 (2.95; 4.37) | 21.0% | 16.1% (8.4%; 23.7%) |
DTaP at 4 months | 24.3% (64/263) | 9.8% (292/2982) | 14.5% | 13.8% (13.4%; 14.0%) | 2.5 (1.91; 3.18) | 18.0% | 10.6% (1.4%; 19.3%) |
DTaP at 6 months | 19.6% (71/362) | 8.3% (217/2616) | 11.3% | 10.5% (10.3%; 10.8%) | 2.3 (1.81; 3.02) | 24.7% | 14% (3.9%; 23.5%) |
Measles at 12 months | 17.5% (99/567) | 4.6% (94/2025) | 12.8% | 8.8% (8.5%; 9.0%) | 2.9 (2.12; 3.85) | 51.3% | 31.8% (20.5%; 40.1%) |
CI Confidence interval estimated using bootstrap with 1000 replications
aAnalysis restricted to the 2-year cohort and to children born in Quebec. Unvaccinated children: 51 at 2 months, 5 at 4 months, 4 at 6 months and 24 at 12 months
bRisk difference estimated with standardization using predicted probabilities calculated from Robust Poisson multivariable regression. Incomplete vaccination for common antigens only (ie. DTaP-VPI-Hib. MMR and Men-C-C vaccines). Risk difference and relative risk adjusted for survey year, mother’s age at child birth, sex, mother’s education, child’s rank, daycare attendance, child’s health condition, gestational age, family type, main vaccine provider, missed opportunities. Analysis restricted to children with no vaccine delays at previous dose. Mother’s language, mother’s country of origin and the birth attendant were excluded from this analysis as they were not collected in 2006 and 2008 (more than 10% of missing)
cSimilar results were observed using the following formula: PCE = proportion of cases exposed (i.e. proportion of children with incomplete vaccination status with new vaccine delays)